Tenax Therapeutics Inc SEC Filings

Tenax Therapeutics (TENX) filed a Form 4 disclosing insider activity by director Michael H. Davidson on 1 July 2025.

• Equity grant: Davidson acquired 80,000 stock options with an exercise price of $5.75. The options become exercisable on 01-Jul-2026 and expire on 01-Jul-2035. No cash was paid at grant (price $0.00).
• Existing derivative holdings: The filing shows additional option positions of 100,000 options at $5.94, two small option lots (4 each) at $3,200 and $992, a 47,500 pre-funded warrant (strike $0.01, no expiration) and a 25,000 warrant (strike $4.50) that will lapse upon the earlier of several milestone events or 08-Aug-2029.
• Common shares: Davidson owns 2,881 shares directly after the reported transaction.
• Total derivative exposure: The table indicates 252,508 derivative securities (options + warrants) now beneficially owned.

No sales or dispositions of Tenax common stock were reported. The transactions appear to be part of routine director compensation and warrant structures related to prior financing rounds.

Tenax Therapeutics, Inc. (TENX) – Form 4 insider transaction

Director Declan Doogan reported one new equity award and disclosed his updated holdings:

• 80,000 stock options acquired on 07/01/2025 (Code A). The options are immediately exercisable at $5.75 and expire on 07/01/2035.
• Existing derivative positions include 100,000 options exercisable at $5.94 (expire 12/10/2034) and two small option lots of 4 shares each at much higher strike prices ($992 and $3,200).
• Non-derivative ownership remains at 2,274 shares of common stock.

The filing shows no open-market purchase or sale of common shares; the activity is limited to an option grant. The report was signed on 07/03/2025 and was filed by a single reporting person.

Because the option strike price is significantly above recent grant levels disclosed in prior filings and involves a director rather than an executive officer, the transaction is generally viewed as routine compensation and does not suggest an immediate change in the company’s fundamentals or insider sentiment.

LanzaTech Global, Inc. has filed its definitive 2025 proxy (Schedule 14A) for the virtual Annual Meeting set for July 28, 2025. Stockholders of record on June 3, 2025 (231.96 million common and 20 million Series A Preferred shares) will vote on ten proposals.

Key corporate actions requested:

• Elect two Class II directors (Barbara Byrne and Reyad Fezzani) for terms ending 2028.
• Ratify Deloitte & Touche LLP as independent auditor for FY-2025.
• Advisory “say-on-pay” vote for named executive officers.
• Increase authorized common shares from 600 million to 2.58 billion (total capital stock to 2.6 billion) to cover new securities.
• 100-for-1 reverse stock split with proportional decrease in authorized shares post-split and related reduction of par value to $0.0000001.
• Enable stockholder action by written consent.
• Approve possible “change of control” and 19.9% issuance thresholds under Nasdaq Rules 5635(b)/(d).
• Permit adjournment if additional proxy solicitation is required.

Financing background: On May 7 2025 the company sold 20 million Series A Convertible Senior Preferred Shares for $40 million to LanzaTech Global SPV, LLC. The same agreement requires the company to issue a warrant for 780 million common shares at $0.0000001 per share and to pursue a subsequent cash financing of $35–60 million at $0.05 per share within 45 days of receiving stockholder approvals. The warrant becomes exercisable only after (i) stockholder approval of all Special Proposals and (ii) completion of the subsequent (or alternative) financing, and will self-exercise on a cashless basis if these conditions are met before May 7 2026.

Consequences of the vote: Approval provides capital structure flexibility, satisfies obligations under the Purchase Agreement and removes a 39.36 million-vote cap on the Series A Preferred, but will significantly dilute existing common holders once the preferred converts, the warrant auto-exercises and additional shares are sold. Failure to approve could block the warrant exercise, jeopardise the planned financing and trigger a mandatory redemption obligation on the preferred shares, for which liquidity is uncertain.

Tenax Therapeutics, Inc. (TENX) – Form 4 filing dated 07/03/2025

The filing reports equity incentive activity for Robyn Hunter, a director of Tenax Therapeutics. On 07/01/2025 Ms. Hunter received a new stock-option grant for 80,000 shares of common stock at an exercise price of $5.75 per share. The options become exercisable on 07/01/2026 and expire on 07/01/2035. Following this grant she directly holds:

• 80,000 options (strike $5.75; granted 07/01/2025)
• 4 options (strike $992; expiry 06/09/2032)
• 100,000 options (strike $5.94; expiry 12/10/2034)

No open-market purchases or sales of Tenax common shares are reported; all transactions involve derivative securities (stock options). The filing reflects a routine equity award to a non-employee director and does not modify direct share ownership.

BBVA (NYSE: BBVA) has cleared a pivotal regulatory hurdle in its planned acquisition of Banco de Sabadell. The Spanish Council of Ministers, in its session of 24 June 2025, approved the economic concentration arising from BBVA’s voluntary tender offer for 100% of Sabadell’s share capital. This authorization follows the Spanish competition authority’s approval on 30 April 2025 and is granted with an additional, undisclosed condition beyond the commitments BBVA had already presented.

Under Article 26.1(c) of Royal Decree 1066/2007, BBVA could have withdrawn the offer because the clearance is conditional. After reviewing the Council’s resolution, BBVA decided to keep the offer in force, signalling management’s confidence in meeting the new requirement and completing the transaction.

• Form type: 6-K (foreign issuer current report)
• Transaction: Voluntary tender offer for Banco de Sabadell, originally announced 9 May 2024
• Key date: Council approval issued 24 June 2025; BBVA confirmation dated 30 June 2025
• Regulatory status: Spanish merger-control process now concluded

The filing contains no financial figures or earnings updates, focusing solely on the regulatory progress of the proposed acquisition.